ABL1 V299L
Gene Variant Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene ABL1
Variant V299L
Impact List missense
Protein Effect unknown
Gene Variant Descriptions ABL1 V299L lies within the protein kinase domain of the Abl1 protein (UniProt.org). ABL1 V299L has been demonstrated to occur as a secondary resistance mutation in the context of BCR-ABL1 (PMID: 18242697, PMID: 23086624, PMID: 30419862), but has not been biochemically characterized and therefore, its effect on Abl1 protein function is unknown (PubMed, Nov 2025).
Associated Drug Resistance Y
Category Variants Paths

ABL1 mutant ABL1 V299L

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Transcript NM_005157.6
gDNA chr9:g.130872201G>C
cDNA c.895G>C
Protein p.V299L
Source Database RefSeq
Genome Build GRCh38/hg38
Transcript gDNA cDNA Protein Source Database Genome Build
NM_005157 chr9:g.130872201G>C c.895G>C p.V299L RefSeq GRCh38/hg38
NM_007313.2 chr9:g.130872144G>C c.895G>C p.V299L RefSeq GRCh38/hg38
NM_005157.5 chr9:g.130872201G>C c.895G>C p.V299L RefSeq GRCh38/hg38
NM_007313.3 chr9:g.130872144G>C c.895G>C p.V299L RefSeq GRCh38/hg38
NM_005157.6 chr9:g.130872201G>C c.895G>C p.V299L RefSeq GRCh38/hg38
NM_007313 chr9:g.130872144G>C c.895G>C p.V299L RefSeq GRCh38/hg38

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT02228382 FDA approved Bosutinib Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Terminated USA | SWE | NOR | ITA | FRA | ESP | DEU | AUT 0
NCT03106779 Phase III Bosutinib Asciminib Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs Completed USA | TUR | ROU | NLD | LBN | ITA | ISR | HUN | GBR | FRA | ESP | DEU | CZE | CHE | CAN | BRA | BGR | AUS | ARG 6
NCT01593254 Phase II Imatinib Dasatinib Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) Completed USA | POL | ITA | HUN | FRA | ESP | CZE | CAN | BRA | BEL | AUT | ARG 3